Literature DB >> 26344738

A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy.

Shannon M Clark1, Holly E Dunn2, Gary D V Hankins2.   

Abstract

Hypertension is the most commonly encountered medical condition in pregnancy, contributing significantly to maternal and perinatal morbidity and mortality. Mild to moderate hypertension in pregnancy is defined as systolic blood pressure of 140-159 mmHg or diastolic blood pressure of 90-109 mmHg (7-9% of pregnancies). When treating hypertension in pregnancy, not only do physiologic changes of pregnancy have an effect on the pharmacokinetics and pharmacodynamics of the drugs used, but the pathophysiology of hypertensive disorders of pregnancy also have an effect. To date, evidence is lacking on the pharmacokinetics and pharmacodynamics of commonly used antihypertensive drugs, which often times leads to suboptimal treatment of hypertensive pregnant women. When considering which agents to use for treatment of mild to moderate hypertension, specifically in gestational and chronic hypertension, oral labetalol and nifedipine are valid options. An overview of the profile for use, safety, and current pharmacokinetic data for each agent is presented here.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26344738     DOI: 10.1053/j.semperi.2015.08.011

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  13 in total

1.  Phytosterol enhances oral nifedipine treatment in pregnancy-induced preeclampsia: A placebo-controlled, double-blinded, randomized clinical trial.

Authors:  Mei Zhang; Huanrong Feng
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-01

Review 2.  The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.

Authors:  Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-11       Impact factor: 4.481

Review 3.  Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question).

Authors:  Giorgina Barbara Piccoli; Gianfranca Cabiddu; Rossella Attini; Silvia Parisi; Federica Fassio; Valentina Loi; Martina Gerbino; Marilisa Biolcati; Antonello Pani; Tullia Todros
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 4.  Regulators of G protein signaling in cardiovascular function during pregnancy.

Authors:  Katherine J Perschbacher; Guorui Deng; Rory A Fisher; Katherine N Gibson-Corley; Mark K Santillan; Justin L Grobe
Journal:  Physiol Genomics       Date:  2018-04-27       Impact factor: 3.107

5.  Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes.

Authors:  Raju Khatri; John K Fallon; Craig Sykes; Natasha Kulick; Rebecca J B Rementer; Taryn A Miner; Amanda P Schauer; Angela D M Kashuba; Kim A Boggess; Kim L R Brouwer; Philip C Smith; Craig R Lee
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

6.  Vitamin D Enhances Efficacy of Oral Nifedipine in Treating Preeclampsia with Severe Features: A Double Blinded, Placebo-Controlled and Randomized Clinical Trial.

Authors:  Dan-Dan Shi; Yong Wang; Jun-Jun Guo; Ling Zhou; Na Wang
Journal:  Front Pharmacol       Date:  2017-11-24       Impact factor: 5.810

7.  Improving Safe and Effective Use of Drugs in Pregnancy and Lactation: Workshop Summary.

Authors:  Laura E Riley; Alison G Cahill; Richard Beigi; Renate Savich; George Saade
Journal:  Am J Perinatol       Date:  2017-01-31       Impact factor: 1.862

8.  Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression.

Authors:  Raju Khatri; Natasha Kulick; Rebecca J B Rementer; John K Fallon; Craig Sykes; Amanda P Schauer; Melina M Malinen; Merrie Mosedale; Paul B Watkins; Angela D M Kashuba; Kim A Boggess; Philip C Smith; Kim L R Brouwer; Craig R Lee
Journal:  J Pharm Sci       Date:  2020-09-12       Impact factor: 3.534

9.  Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia.

Authors:  Jian Ding; Yan Kang; Yuqin Fan; Qi Chen
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

10.  A double-blinded, randomized, placebo-controlled trial assessing the effects of nifedipine on embryo transfer: Study protocol.

Authors:  Kelvin Kl Ng; Genia Rozen; Tanya Stewart; Franca Agresta; Alex Polyakov
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.